These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 21575627

  • 1. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M, Fuks B, Leclercq K, Matagne A.
    Eur J Pharmacol; 2011 Aug 16; 664(1-3):36-44. PubMed ID: 21575627
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABAA Receptor.
    Wood M, Daniels V, Provins L, Wolff C, Kaminski RM, Gillard M.
    J Pharmacol Exp Ther; 2020 Jan 16; 372(1):1-10. PubMed ID: 31619465
    [Abstract] [Full Text] [Related]

  • 7. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD, Gillard M.
    Epilepsia; 2017 Feb 16; 58(2):255-262. PubMed ID: 28012162
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD, Sands ZA, Vandenplas C, Gillard M.
    Epilepsia; 2018 Sep 16; 59(9):e147-e151. PubMed ID: 30144048
    [Abstract] [Full Text] [Related]

  • 10. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
    Finnema SJ, Rossano S, Naganawa M, Henry S, Gao H, Pracitto R, Maguire RP, Mercier J, Kervyn S, Nicolas JM, Klitgaard H, DeBruyn S, Otoul C, Martin P, Muglia P, Matuskey D, Nabulsi NB, Huang Y, Kaminski RM, Hannestad J, Stockis A, Carson RE.
    Epilepsia; 2019 May 16; 60(5):958-967. PubMed ID: 30924924
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy.
    Kaminski RM, Matagne A, Leclercq K, Gillard M, Michel P, Kenda B, Talaga P, Klitgaard H.
    Neuropharmacology; 2008 Mar 16; 54(4):715-20. PubMed ID: 18207204
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B.
    Proc Natl Acad Sci U S A; 2004 Jun 29; 101(26):9861-6. PubMed ID: 15210974
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Brivaracetam prevents astroglial l-glutamate release associated with hemichannel through modulation of synaptic vesicle protein.
    Okada M, Fukuyama K, Shiroyama T, Ueda Y.
    Biomed Pharmacother; 2021 Jun 29; 138():111462. PubMed ID: 33706129
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Brivaracetam: First Global Approval.
    Markham A.
    Drugs; 2016 Mar 29; 76(4):517-22. PubMed ID: 26899665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.